Abstract
Clinical research is a costly and time-consuming enterprise. Only a handful among thousands of test compounds make it to the clinical research phase, and of these, only one or two might gain market approval. The process can take over a decade, and cost hundreds of millions of dollars. During this time, competitors may undercut a company, or patent protection may expire. Industry further faces the challenges of increasing regulatory burdens for approval of medications, more complex clinical trials, and a limit to the number of available investigators and volunteers in the United States. This has led to a push for regulatory relief, information technology, and the adoption of global standards for conducting trials outside the United States.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maxmen A. Drug development: a combined effort. Nature. 2013;502(7470):S4–6.
Woodcock J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther. 2012;91(3):378–80.
DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013;94(3):329–35.
Eapen ZJ, Vavalle JP, Granger CB, Harrington RA, Peterson ED, Califf RM. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J. 2013;165(6):837–47.
Mullard A. Multicompany trials adapt to disciplines beyond cancer. Nat Med. 2014;20(1):3.
Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014;9(1):27–39.
Fong S. Market watch: upcoming market catalysts in Q4 2013. Nat Rev Drug Discov. 2013;12(10):731.
Lenzer J. Why we can’t trust clinical guidelines. BMJ. 2013;346:f3830.
Hede K. Project data sphere to make cancer clinical trial data publicly available. J Natl Cancer Inst. 2013;105(16):1159–60.
Briscoe C. Laboratory and software applications for clinical trials: the global laboratory environment. Bioanalysis. 2011;3(21):2381–4.
So D, Joly Y, Knoppers BM. Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry. Public Health Genomics. 2013;16(6):322–35.
Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.
Stone K. Should ethics standards for overseas trials get a makeover?: transparency in overseas medical research has improved, but several issues concerning ethics of protections for trial participants remain unsolved. Ann Neurol. 2013;74(1):A7–10.
Desmond-Hellmann S. Improving health with partnerships between academia and industry. JAMA Intern Med. 2013;173(12):1051–2.
Flaatten H, Haney M, Wernerman J. The Scandinavian Critical Care Trials Group: producing important new findings in challenging times. Acta Anaesthesiol Scand. 2013;57(2):138–40.
Allison M. Reinventing clinical trials. Nat Biotechnol. 2012;30(1):41–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nasir, A. (2015). Industry. In: Nasir, A. (eds) Clinical Dermatology Trials 101. Springer, Cham. https://doi.org/10.1007/978-3-319-09027-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-09027-6_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09026-9
Online ISBN: 978-3-319-09027-6
eBook Packages: MedicineMedicine (R0)